Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System AtrophyMASCOT, a global phase III randomized, double-blind, placebo-controlled trial, will assess the efficacy ...

Japanese drugmaker Chugai, which is majority owned by Roche, On Friday revealed that Zenyaku Kogyo has obtained regulatory ...

Researchers have developed a new optical biosensor to detect the monkeypox virus. The biosensor can provide results in 20 minutes. The new technology ...

mAbs 2014; 6 (2):523-532). Cusatuzumab is currently being evaluated in patients ... Cusatuzumab is a first-in-class high-affinity humanized monoclonal antibody targeting CD70, an immune checkpoint ...

Oppenheimer began coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research note issued to ...

Stock recommendation on SIGA Technologies affected by mpox outbreak response, diversifying into mAbs for orthopoxviruses, remains speculative buy.

Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable TherapeuticsJUPITER, Fla., Nov. 21, ...

Researchers suggest broadly reactive antibodies identified are likely to represent a common mechanism of acquired immunity to ...

Casirivimab and imdevimab in combination is safe among pediatric outpatients with at least 1 risk factor for severe COVID-19.

Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its ...